Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Pulmatrix Inc
NASDAQ PULM
Data sourced from
and
and
Pulmatrix Inc Days Sales Outstanding (DSO) 5 year CAGR for the year ending December 31, 2023
Pulmatrix Inc Days Sales Outstanding (DSO) 5 year CAGR is NA for the year ending December 31, 2023. The days sales outstanding ratio measures the average number of days it takes for a company to collect payment from its customers. It is calculated by dividing receivables by revenue and then multiplying by 365. This ratio indicates the average collection period for accounts receivable and provides insights into the effectiveness of the company's credit and collection policies. A shorter period indicates faster collection and better cash flow management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Pulmatrix Inc Days Sales Outstanding (DSO) for the year ending December 31, 2022 was 78.04, a 1,549.48% change year over year.
-
Pulmatrix Inc Days Sales Outstanding (DSO) for the year ending December 31, 2021 was 4.73, a 94.95% change year over year.
-
Pulmatrix Inc Days Sales Outstanding (DSO) for the year ending December 31, 2020 was 2.43, a -99.27% change year over year.
-
Pulmatrix Inc Days Sales Outstanding (DSO) for the year ending December 31, 2019 was 332.24, a 0.00% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: PULM
| CEO | Mr. Teofilo David Raad MBA |
| IPO Date | March 21, 2014 |
| Location | United States |
| Headquarters | 99 Hayden Avenue, Lexington, MA, United States, 02421 |
| Employees | 22 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Key trends
StockViz Staff
September 20, 2024
Any question? Send us an email